(Q44182799)

English

Effects of short- and long-term (--)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain

scientific article published in October 2002

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Effects of short- and long-term (--)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

Grazyna Kunikowska

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Imelda Gallagher

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Vivette Glover

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Angela Clow

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Peter Jenner

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

language of work or name

0 references

publication date

1 October 2002

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

953

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1-2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1-11

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

A high dose of long term treatment with deprenyl loses its effect on antioxidant enzyme activities as well as on survivals of Fischer-344 rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

(-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

(-) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Sequential changes in activities of superoxide dismutase and catalase in brain regions and liver during (-)deprenyl infusion in male rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Age-related changes in antioxidant enzyme activities are region and organ, as well as sex, selective in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

The optimal dosage of (-)deprenyl for increasing superoxide dismutase activities in several brain regions decreases with age in male Fischer 344 rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

The ability of (-)deprenyl to increase superoxide dismutase activities in the rat is tissue and brain region selective

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

The effect of a long term (6 months) treatment with (-)deprenyl on antioxidant enzyme activities in selective brain regions in old female Fischer 344 rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

(?)-Deprenyl can induce soluble superoxide dismutase in rat striata

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

CuZn-superoxide dismutase transgenic mice: no effect on longevity, locomotor activity and 3H-mazindol and 3H-spiperone binding over 19 months

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Long-term effects of pergolide and (-)-deprenyl on 3H-mazindol and 3H-spiperone binding in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Pharmacology of selegiline

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Oxidative stress and the pathogenesis of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

(-)Deprenyl increases the life span as well as activities of superoxide dismutase and catalase but not of glutathione peroxidase in selective brain regions in Fischer rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Assessing the effects of deprenyl on longevity and antioxidant defenses in different animal models

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl: a possible antioxidant strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Upregulation of antioxidant enzyme activities by deprenyl. Implications for life span extension

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

(-)Deprenyl-Medication: A Strategy To Modulate the Age-Related Decline of the Striatal Dopaminergic System

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

The Pharmacological Profile of (-)Deprenyl (Selegiline) and its Relevance for Humans: A Personal View

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

The distribution of copper, zinc- and manganese-superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Maintenance on L-deprenyl prolongs life in aged male rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Selegiline as initial treatment in de novo parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Treatment with L-deprenyl prolongs life in elderly dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Mitochondria in neurodegenerative apoptosis: an opportunity for therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Maintaining mitochondrial membrane impermeability. an opportunity for new therapy in glaucoma?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

Effect of MPTP and l‐Deprenyl on Antioxidant Enzymes and Lipid Peroxidation Levels in Mouse Brain

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

The pharmacology of selegiline ((-)deprenyl). New aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903187-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0006-8993(02)03187-6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44182799&oldid=2108320196"